We have previously demonstrated, using a derivate of the ERα-positive breast cancer cell line MCF-7 engineered to express ERβ2, that ERβ2 heterodimerizes with ERα and inhibits ligand induced ERα transcriptional activity by inducing proteasome-dependent degradation of ERα [18]. The gene discussed is ESR1; the disease is breast carcinoma.